Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Medtronic
Boehringer Ingelheim
McKesson
Dow

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR IOFLUPANE I-123


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ioflupane I-123

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01141023 ↗ Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Active, not recruiting Institute for Neurodegenerative Disorders Phase 2 2010-06-01 This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.
NCT01141023 ↗ Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Active, not recruiting Ken Marek, MD Phase 2 2010-06-01 This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.
NCT01453127 ↗ DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation Mayo Clinic Phase 4 2011-10-01 The investigators propose using DaTscan in patients with REM sleep behavior disorder (RBD), mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test several hypotheses - some confirmatory, and some novel. Such use will provide new data on the potential clinical and research utility of DaTscan in neurodegenerative diseases. The findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of neurodegenerative diseases.
NCT03185182 ↗ Diagnostic Imaging for Clear Cell Renal Cell Carcinoma Terminated Lund University Phase 2 2017-07-14 The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.
NCT03185182 ↗ Diagnostic Imaging for Clear Cell Renal Cell Carcinoma Terminated Region Skane Phase 2 2017-07-14 The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.
NCT03582488 ↗ Longitudinal Imaging Biomarkers of Disease Progression in DLB Enrolling by invitation Kejal Kantarci Phase 4 2018-06-25 The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ioflupane I-123

Condition Name

Condition Name for Ioflupane I-123
Intervention Trials
REM Sleep Behavior Disorder 3
Pre-motor Parkinson Disease 2
Symptomatic Parkinson Disease 2
Parkinson Disease(PD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ioflupane I-123
Intervention Trials
Parkinson Disease 4
REM Sleep Behavior Disorder 3
Mental Disorders 3
Parkinsonian Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ioflupane I-123

Trials by Country

Trials by Country for Ioflupane I-123
Location Trials
United States 20
China 7
Austria 1
Greece 1
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ioflupane I-123
Location Trials
California 3
Florida 2
Minnesota 2
Oregon 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ioflupane I-123

Clinical Trial Phase

Clinical Trial Phase for Ioflupane I-123
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ioflupane I-123
Clinical Trial Phase Trials
Enrolling by invitation 3
Recruiting 2
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ioflupane I-123

Sponsor Name

Sponsor Name for Ioflupane I-123
Sponsor Trials
PPD 2
GE Healthcare 2
Cedars-Sinai Medical Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ioflupane I-123
Sponsor Trials
Other 8
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Dow
Merck
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.